Moxifloxacin Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Fresenius Kabi, is a fluoroquinolone presented as an intravenous solution for intravenous use. It treats a range of serious bacterial infections in adult patients, including community‑acquired bacterial pneumonia, acute bacterial sinusitis, skin and skin‑structure infections, and complicated intra‑abdominal infections.

GNH USA supplies Moxifloxacin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is a fluoroquinolone antibacterial used to treat infections caused by susceptible bacteria. - Community‑acquired bacterial pneumonia: Improves clinical outcomes and resolves infection in adult patients. - Acute bacterial sinusitis: Reduces sinus inflammation and bacterial load, leading to symptom relief. - Skin and skin‑structure infections: Achieves bacterial eradication and promotes healing of infected skin lesions. - Complicated intra‑abdominal infections: Provides effective coverage against mixed aerobic and anaerobic pathogens in severe abdominal infections.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertigo. - Elevated liver enzymes: mild, reversible increase in transaminases. - Photosensitivity: increased skin sensitivity to sunlight.

Serious or Rare Side Effects: - Tendon rupture: risk of tendonitis or rupture, especially in older adults. - QT interval prolongation: may cause cardiac arrhythmias. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or anaphylaxis.

When using Moxifloxacin, clinicians should consider several precautionary measures to minimize risks. - Renal impairment: adjust therapy or monitor renal function in patients with reduced clearance. - Hepatic dysfunction: use with caution in liver disease and monitor liver enzymes. - QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances. - Concomitant fluoroquinolones: avoid concurrent use with other quinolones to prevent additive toxicity. - Tendon disorders: discontinue promptly if tendon pain or inflammation occurs. - Store at ambient temperature: keep vials below 25°C, protect from light and moisture, and use within the expiry date.

Moxifloxacin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption; separate administration by at least 2 hours. - Warfarin: may increase INR and bleeding risk; monitor coagulation parameters closely. - Cytochrome P450 1A2 inhibitors (e.g., fluvoxamine): increase moxifloxacin plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of CNS stimulation or seizures. - Theophylline: potential for increased serum concentrations; monitor for toxicity. - Corticosteroids: combined use may raise risk of tendon rupture.